COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26/07/2024
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its [...]
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
26/07/2024
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) [...]
OneMedNet Announces $4.6 Million Private Placement
26/07/2024
Institutional investors include affiliates of Off the Chain Capital and Discovery Capital Management MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), [...]
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26/07/2024
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 [...]
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26/07/2024
Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical [...]
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
26/07/2024
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1 ,2,3,4 In the [...]
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
26/07/2024
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and COMMACK, NY, July [...]
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results [...]
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise [...]
Genetic Technologies Strategic Restructure Driving USA Sales Growth
26/07/2024
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
26/07/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
26/07/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), 26 juillet 2024 - GENFIT (Nasdaq et Euronext : GNFT) , une société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
26/07/2024
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
26/07/2024
If approved, Yuvanci ® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended [...]
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26/07/2024
TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024
26/07/2024
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months [...]
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
26/07/2024
Ipsen receives CHMP positive opinions for Iqirvo ® (elafibranor) in Primary Biliary Cholangitis and Kayfanda ® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases CHMP positive opinion for Iqirvo ® ( [...]
Ipsen reçoit des avis positifs du CHMP pour Iqirvo® (elafibranor) dans la cholangite biliaire primitive et Kayfanda® (odévixibat) dans le syndrome d'Alagille, deux maladies rares du foie cholestatiques
26/07/2024
Le CHMP a émis un avis positif concernant Iqirvo ® (elafibranor) pour le traitement de la cholangite biliaire primitive, à la suite de l’approbation de la FDA en juin 2024. Le CHMP a émis un avis positif concernant [...]
Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
26/07/2024
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark, July 26, 2024 – Bavarian [...]

Pages